Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
CAMBRIDGE, Mass., Nov. 28, 2016 -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the 28th Annual Piper Jaffray Healthcare Conference, being held on November 29-30 in New York City.
| 28th Annual Piper Jaffray Healthcare Conference | ||
| Date: | Wednesday, November 30 | |
| Time: | 1:00 pm Eastern Time | |
| Location: | The Lotte New York Palace Hotel, Holmes I Room | |
| Webcast: | http://edge.media-server.com/m/p/cfdngzft | |
About CoLucid Pharmaceuticals, Inc.
CoLucid is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
CONTACT Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (857) 285-6494 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568
